Navigation Links
Pharsight to Present at eClinical Forum
Date:2/25/2008

Dr. Jon Wagg Will Present on Improving Clinical Research Productivity

MOUNTAIN VIEW, Calif., Feb. 25 /PRNewswire-FirstCall/ -- Pharsight Corporation (Nasdaq: PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced that Jonathan Kuwabara-Wagg, MD, Ph.D., Senior Scientist, will lead a lecture on improving clinical research planning on February 26, 2008 at 14:00 pm local time at the eClinical Forum conference in Geneva, Switzerland.
Dr. Wagg will present on the following topics:

-- FDA and the Critical Path in the context of the pharmaceutical R&D

drought

-- The Innovative Medicines Initiative

-- Model Based Drug Development -- What is it and how can it improve R&D

productivity?

-- Need for IT Infrastructure to Support Modeling and Simulation

For more information on the conference please go to the following address: http://www.eclinicalforum.com/.

About Pharsight Corporation

Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. Pharsight's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.

Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every l
'/>"/>

SOURCE Pharsight Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Pharsight Files Application for Nasdaq Capital Market Listing
2. Pharsight to Host European Software Conference
3. Pharsight Expands Global Consulting Services Teams
4. Pharsight Achieves $7.3 Million in Quarterly Revenue
5. Pharsight to Present at DIA Cardiac Safety Conference on December 4, 2007
6. FDA and Pharsight Continue to Collaborate Under CRADA
7. Pharsight to Host Webinar on Hepatitis C Virus (HCV) and HIV Drug-Disease Modeling
8. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
9. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
10. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
11. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/6/2008)...ospital Ship Serving in West Africa Receives Acces...ley, Texas October 6, 2008 -- www.seamobile.com [S... of communications services to remote locations, a...oxNews channel via satellite to Mercy Ships onboar... The Africa Mercy is the world,s largest non-gove...
(Date:10/5/2008)...iderable disparities in survival related to race a...and neck cancer. Published in the November 15, 200...e American Cancer Society, the study indicates tha...t could improve outcomes for these cancers among A...dies have examined disparities in cancer survival ...
(Date:10/5/2008)...ifficult to kill a spider as it scurries across th...er set foot on a plane. While nothing physically ...r can keep them from the task at hand. , The sam...hysical activity, according to research presented ... , Researchers from the Center for Obesity Resea...
(Date:10/3/2008)...ide Komen Community Challenge Campaign to Close,th...come Women and Women of ... Pennsylvania House Speaker Dennis,O,Brien (R-169t... survivors,and advocates from the Philadelphia Aff...ic forum this morning to call for policies to clos...
Breaking Medicine News(10 mins):Health News:Seamobile Provides Foxnews To Mercy Ships 2Health News:Seamobile Provides Foxnews To Mercy Ships 3Health News:News from Cancer: Disparities in head and neck cancer patients 2Health News:Mental barriers hamper obese women's efforts to get exercise 2Health News:Susan G. Komen for the Cure(R), Speaker Dennis O'Brien, Obama and McCain Health Care Advisors, Breast Cancer Survivors and Advocates Call for Needed Health Care Reforms 2Health News:Susan G. Komen for the Cure(R), Speaker Dennis O'Brien, Obama and McCain Health Care Advisors, Breast Cancer Survivors and Advocates Call for Needed Health Care Reforms 3
...iovascular disease, despite the lofty claims of it...cent trial has shown.// The findings of the trial ... American Journal of Epidemiology. Selenium now jo...vitamins C and E in particular, that were praised ...
..., Human Development, and Health at Harvard School ...for US society //and has found that the disease co...n. Ganz has published his research in the new book... Treatment (CRC Press, 2006). In his study, titled...
...not mean anything to the deadly H5N1 virus as wa...the poultry// flocks in several parts of Asia, acc...d earlier that the activity of the bird-flu virus ...months from October to March when temperatures are...
...quences. People who are in their 60s and 70s shoul...eases their physical function// and helps them to ...of functional independence in the community, by pr...illareal from Washington University School of Medi...
Other Medicine News:Health News:The Price Of Autism 2
(Date:10/6/2008)...ntific Conference -, ORLANDO, Fla., Oct. 6 /PRNew...bia) today announced presentation of data from a p...at cyclic guanosine,monophosphate (cGMP) plays in ...rate that cGMP inhibits intestinal pain in a precl...itizes colonic afferent nerves in a,similar model ...
(Date:10/6/2008)...py is More Likely to Induce Steroid-Free Remissi... Immunomodulator, Azathioprine, OR... for the first time,from the Phase 3b Study of Pat...rs and Biologic Therapy (SONIC) may provide new in...moderate to severe Crohn,s disease.,According to f...
(Date:10/6/2008)...Naltrexone SR Associated with Bette.... 6 /- Orexigen Therapeutic...any focused on the treatment of,obesity and other ...esented,data showing the investigational drug, Con...lly achieved key objectives (lowered naltrexone,Cm...
(Date:10/5/2008)...f Medicine reaffirm,well-established efficacy and ...R), RIDGEFIELD, Conn., and NEW YORK, Oct. 5 /PRNe...tential Long-term Impacts on Function with,Tiotrop...tiotropium bromide,inhalation powder), sustained i...measured by FEV(1) (p<0.001) versus placebo in Chr...
Breaking Medicine Technology:Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain 2Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain 3New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 2New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 3New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 4New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 5New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 6New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 7New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 8Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 2Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 3Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 4Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 5Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 2Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 3Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 4Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 5Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 6Delivering Molecular Imaging Solutions Across Clinical Specialties 3A Siemens Showcases New Technologies at RSNA 2007 1871 1Delivering Molecular Imaging Solutions Across Clinical Specialties 3A Siemens Showcases New Technologies at RSNA 2007 1871 2Delivering Molecular Imaging Solutions Across Clinical Specialties 3A Siemens Showcases New Technologies at RSNA 2007 1871 3Delivering Molecular Imaging Solutions Across Clinical Specialties 3A Siemens Showcases New Technologies at RSNA 2007 1871 4Delivering Molecular Imaging Solutions Across Clinical Specialties 3A Siemens Showcases New Technologies at RSNA 2007 1871 5Regular exercise reduces risk of blood clots 6712 1Evolutionary comparison finds new human genes 1289 1Evolutionary comparison finds new human genes 1289 2Evolutionary comparison finds new human genes 1289 3New book presents methods to poke and prod individual molecules 1284 1New book presents methods to poke and prod individual molecules 1284 2
...ides Update to Timeline for Second Pivotal Phase 3...irstCall/ -- Advanced Life,Sciences Holdings, Inc....l efficacy data from Trial CL-06, the first of two...s the safety and,effectiveness of cethromycin, a n...ommunity acquired pneumonia (CAP). The Company,als...
...HINGTON, January 29, 2007 /PRNewswire-USNewswire/ ...), the President,s,Malaria Coordinator, announced ...Deputy Coordinator of the President,s Malaria,Init... in the U.S.,Public Heath Service and has most rec...luation, at the Global Fund to Fight,AIDS, Tubercu...
Other Medicine Technology:Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 2Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 3Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 4Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 5Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 6Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 7Studies of Drug Resistance May Lead to Individual Therapy for Rare,Cancers 2
With this unique offer, you can prepare for any molecular biology application. Pipetman P2 and P10 are ideal for enzymes and reagents, and P100 is perfect for buffers. Kits include Diamond Filter Tip
The RapidPCP test is an immunochromatography based one step in vitro test. It is,designed for qualitative determination of Phencyclidine in human urine specimens above,a cut-off level of 25 ng/mL. Th
... an immunochromatography based one step,in vitro t...of Opiates and its metabolite in,human urine speci...e a cut-off level,of 2,000ng/mL can be detected. T...are,location and is for use by Healthcare Professi...
All of DOA Panel Test is an immunochromatography based one step in vitro test. It is designed,for qualitative determination of drug substances in human urine specimens. This assay has not,been evalua
Medicine Products: